Top brokers name 3 ASX small cap shares to buy

Immutep Ltd (ASX:IMM) and these small cap ASX shares have been named as buys by brokers. Here's why they are bullish on them…

| More on:
Businessman with hands on hips looks at share price chart with the words 'buy' and 'sell '

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

As well as covering large caps like Afterpay Ltd (ASX: APT) and Telstra Corporation Ltd (ASX: TLS), many brokers also cover smaller companies.

In light of this, I thought I would scour through a range of recent notes to see which small cap ASX shares are in favour with brokers at present.

Three that have been given buy ratings are listed below. Here's why brokers like them:

Immutep Ltd (ASX: IMM)

According to a note out of Bell Potter, its analysts have a speculative buy rating and 85 cents price target on this biotechnology company's shares. The broker notes that Immutep has recently been granted Fast Track status by the US FDA for its efti product candidate. This relates to a trial for first line recurrent or metastatic head and neck squamous cell carcinoma (HNSCC). The broker has increased the probability of success for the treatment in response to this and envisages licensing deals in 2023 if all goes to plan. The Immutep share price is fetching 44.5 cents this afternoon.

Silk Laser Australia Ltd (ASX: SLA)

Analysts at Ord Minnett currently have a buy rating and $5.06 price target on this laser, skin care, and cosmetic injections company's shares. According to the note, the broker was very happy with Silk Laser's performance during the first half. It notes that demand was so strong that the company upgraded its earnings guidance. Positively, Ord Minnett appears confident that Silk can easily achieve the top end of its new guidance range. The Silk Laser share price is trading at $4.50 on Friday.

Telix Pharmaceuticals Ltd (ASX: TLX)

A note out of Wilsons reveals that its analysts have an overweight rating and $5.40 price target on this clinical-stage biopharmaceutical company's shares. According to the note, the broker was pleased to see Novartis report positive results from a trial of Lu-PSMA-617 for prostate cancer. It believes this development is a big positive for Telix, which has a similar therapy – TLX591-CDx. Its ProstACT trial starts soon and will test TLX591 as a second line therapy. The Telix share price is fetching $3.94 on Friday afternoon.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia owns shares of and has recommended Telstra Limited. The Motley Fool Australia owns shares of AFTERPAY T FPO. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Broker Notes

Man with rocket wings which have flames coming out of them.
Broker Notes

These ASX 200 shares could rise 40%+

Big returns could be on offer from these shares according to analysts.

Read more »

a man in a business suite throws his arms open wide above his head and raises his face with his mouth open in celebration in front of a background of an illuminated board tracking stock market movements.
Broker Notes

Analysts say these ASX shares are top buys in June

Brokers are urging investors to buy these shares. Let's find out why.

Read more »

A man in trendy clothing sits on a bench in a shopping mall looking at his phone with interest and a surprised look on his face.
Broker Notes

Brokers name 3 ASX shares to buy today

Here's why brokers are feeling bullish about these three shares this week.

Read more »

Woman and man calculating a dividend yield.
REITs

What price target does Macquarie have on Goodman Group shares?

Goodman Group posted an interesting set of numbers in Q3. Here's Macquarie's take.

Read more »

Miner looking at a tablet.
Broker Notes

Why Macquarie expects this ASX 200 copper stock to surge 36% in a year

Macquarie forecasts some hefty gains ahead for the ASX 200 copper miner. But why?

Read more »

two women celebrating good news on phone
Broker Notes

Top broker names 3 ASX All Ords stocks with between 30% and 77% upside

These 3 stocks offer compelling potential upside.

Read more »

Woman on her phone with diagrams of tech sector related elements linking with each other.
Broker Notes

A leading fund manager is buying these ASX 200 tech shares

Let's see why the fund manager has these shares in its focus portfolio.

Read more »

A young man wearing a black and white striped t-shirt looks surprised.
Broker Notes

Broker says these ASX 200 shares can rise 40% to 80%

Bell Potter sees scope for these shares to rocket from current levels.

Read more »